Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 4Phase NA 3Phase 1/2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Radiation Pneumonitis 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Neoplasms by Site 1Lung Diseases 1Locally Advanced Gastric Cancer 1Esophageal Malignant Neoplasm, Local Recurrence 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced NSCLC 1Advanced Esophageal Cancer 1

Interventions

Cisplatin 31Fluorouracil 24Paclitaxel 19Radiotherapy 15Docetaxel 11Esophagectomy 8Radiation 7Neoadjuvant Therapy 7Carboplatin 7Irinotecan 6Oxaliplatin 5Leucovorin 5Capecitabine 5sintilimab 4pembrolizumab 4camrelizumab 4TP protocol 4Surgical Procedures, Operative 4Drug Therapy 4Chemotherapy, Adjuvant 4Trastuzumab 3Immunotherapy 3Epirubicin 3Chemoradiotherapy 3tislelizumab 2nimotuzumab 2S 1 (combination) 2Radiotherapy, Adjuvant 2Platinum Compounds 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Neoplasms × camrelizumab × Clear all
NCT06086457 2024-07-16

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3 Recruiting
436 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
457 enrolled 9 charts
Gastrointestinal

Esophageal Neoplasms

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

The First Affiliated Hospital of Zhengzhou University

Phase 3 Unknown
234 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT04426955 2021-09-16

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
396 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡